該集團指,虧損擴大因中藥配方顆粒業態受行業政策調整及市場環境變化的影響,銷售收入
及盈利能力下降,導致進一步商譽減值;中成藥業態和中藥材生產及經營業態收入規模及盈利能
力出現下跌;及資產減值、信用減值及部分附屬公司補繳稅款增加,亦對虧
Please share this article if you like it!
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.